Equities
Health CareMedical Equipment and Services
  • Price (USD)339.82
  • Today's Change0.98 / 0.29%
  • Shares traded100.94k
  • 1 Year change-19.63%
  • Beta1.1448
Data delayed at least 15 minutes, as of Aug 11 2022 19:46 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

West Pharmaceutical Services, Inc. is a global manufacturer that is engaged in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. The Company operates through two segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers proprietary packaging, containment, and drug delivery products, along with analytical lab services and other integrated services and solutions, primarily to biologic, generic and pharmaceutical drug customers. The Contract-Manufactured Products segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. This segment manufactures customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.

  • Revenue in USD (TTM)2.93bn
  • Net income in USD685.60m
  • Incorporated1923
  • Employees10.07k
  • Location
    West Pharmaceutical Services Inc530 Herman O. West DriveEXTON 19341United StatesUSA
  • Phone+1 (630) 577-8800
  • Fax+1 (800) 345-9800
  • Websitehttps://www.westpharma.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
ABIOMED, Inc.1.06bn217.58m12.81bn2.00k61.928.7054.3412.624.744.7423.0033.710.66812.1911.75527,367.4013.7616.9114.9618.7581.4882.1320.6023.456.86--0.000.0021.7418.30-39.4721.24-6.64--
Cooper Companies Inc3.14bn948.00m16.07bn12.00k17.462.3412.815.2219.0219.0262.95142.260.3021.816.14261,625.009.1214.0910.4515.9965.9065.0330.2034.480.6882--0.31680.338620.228.241,135.1960.807.030.00
Hologic, Inc.5.23bn1.51bn17.83bn6.71k12.163.619.233.455.945.9420.5420.030.58243.526.35779,433.3016.858.3319.5310.1763.5358.3528.9316.163.3235.740.36270.0049.1414.7467.8241.4210.56--
Insulet Corporation1.18bn34.60m17.95bn2.30k550.9243.12191.5615.460.47650.476516.746.090.58361.457.68512,217.401.710.19891.950.225568.0765.322.940.31743.542.480.76970.0021.4924.52147.06--40.87--
Steris PLC4.77bn376.96m20.90bn16.42k56.213.2821.374.413.743.7447.3764.020.40994.396.33290,654.803.225.333.545.8444.1643.087.8710.081.358.180.318339.1147.5511.90-38.6317.2710.719.17
Align Technology, Inc.3.99bn619.03m21.37bn22.54k36.876.2430.545.637.817.8150.3646.110.71214.474.59177,008.7011.0525.1216.0736.5072.6073.4015.5230.361.15--0.000.0059.9029.63-56.5332.4141.55--
Zimmer Biomet Holdings Inc7.41bn299.60m23.60bn19.50k80.891.9918.573.261.421.0935.2857.820.32430.96835.48379,841.001.321.031.491.1669.5771.164.063.310.94997.030.331977.3511.560.4339400.007.13-1.880.00
West Pharmaceutical Services Inc.2.93bn685.60m24.40bn10.07k37.7210.3431.748.578.988.9838.3332.760.93044.585.81290,968.7021.1714.1125.3516.7840.8735.6122.7516.012.41128.800.094213.6131.8913.4190.7635.688.297.09
Baxter International Inc14.19bn1.01bn29.69bn60.00k30.013.4113.662.132.002.0027.9917.580.5513.656.32236,550.003.976.034.637.2239.1641.587.2010.021.338.000.652138.319.524.7016.52-23.700.658916.53
DexCom, Inc.2.67bn199.70m33.42bn6.30k189.2815.62104.3113.180.47410.47416.525.750.552.675.12424,349.204.115.564.806.5067.1567.297.478.914.305.490.47350.0027.0833.69-68.66--47.52--
ResMed Inc.3.54bn779.48m34.64bn7.97k45.9010.8737.8410.075.315.3124.1022.420.74592.696.60444,101.9016.4311.9819.6214.0356.2957.6622.0217.491.5633.080.171945.578.1111.70-23.676.1311.495.39
Data as of Aug 11 2022. Currency figures normalised to West Pharmaceutical Services Inc's reporting currency: US Dollar USD

Institutional shareholders

46.00%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Mar 20228.42m11.36%
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 20226.38m8.61%
BlackRock Fund Advisorsas of 31 Mar 20224.59m6.19%
SSgA Funds Management, Inc.as of 31 Mar 20223.39m4.58%
Franklin Advisers, Inc.as of 31 Mar 20222.76m3.72%
APG Asset Management NVas of 31 Mar 20222.54m3.43%
Fidelity Management & Research Co. LLCas of 31 Mar 20221.77m2.39%
WCM Investment Management LLCas of 31 Mar 20221.53m2.06%
Geode Capital Management LLCas of 31 Mar 20221.43m1.93%
BlackRock Advisors LLCas of 31 Mar 20221.28m1.72%
More ▼
Data from 31 Mar 2022 - 31 Mar 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.